INTRODUCTION
============

Dieter Gallwitz was the first to discover a yeast-encoded member of the Rab family in the 1980s, when DNA sequencing was just beginning to be widely adopted and required significant effort. Gallwitz found an essential GTP-binding protein that he named Ypt1. It was related to Ras but could not complement the loss of the yeast *RAS1* and *RAS2* genes and thus likely played a different role ([@B25]; see also [@B27]). For his PhD thesis with Randy Schekman, Peter Novick had isolated and described the *SEC* genes responsible for secretion in yeast ([@B18]). After a postdoctoral fellowship on the yeast cytoskeleton with David Botstein at MIT, Novick returned to the secretory pathway for his own lab\'s research and focused on the *SEC* gene products that are required for the delivery of material from the yeast Golgi to the cell surface. The original screen for yeast mutants uncovered 10 genes that, when mutated, accumulated post-Golgi transport vesicles at a nonpermissive temperature ([@B18]). Sequencing of the *SEC4* gene revealed that it encoded a Ras-related protein (Salminen *et al.*, 1987) that was present on secretory vesicles ([@B40]) and was later shown to recruit the so-called Exocyst tether ([@B12]) to help deliver vesicles to the bud tip for fusion ([@B35]). This was the first hint that membrane traffic might require a Ras-like GTPase.

These exciting findings in yeast led several labs to begin the search for mammalian homologues, and Armand Tavitian and Marino Zerial and their colleagues began cloning these relatives. Tavitian named them [Ra]{.ul}s-like proteins from rat [b]{.ul}rain (Rabs; [@B33]; [@B8]), in line with the three-letter nomenclature of other Ras-like protein families; the Rabs were numbered in the random order in which their sequences were obtained; Ypt1 was the homologue of Rab1. Eventually, it would become clear that yeast encode 11 Rabs and human cells encode at least 63 ([@B10]). Most Rabs are stably, C-terminally prenylated on one or (more commonly) two cysteine residues that permit their tight membrane association. Prenylome-wide analysis later revealed that a single cell might contain at least 42 different Rabs ([@B16]); other Rabs are expressed in a more tissue-specific manner.

[@B27] showed that Ypt1 was on the Golgi, in contrast to Sec4, which Novick had shown was present on secretory vesicles. Soon thereafter, Zerial and coworkers raised specific antibodies to their newly discovered gene products and found that these proteins each localized to different membrane compartments ([@B7]). Even more striking was their subsequent discovery, using live-cell microscopy of cells expressing green fluorescent protein (GFP)-- and GFP-variant- tagged proteins, that a single compartment might harbor multiple Rabs, each occupying a distinct microdomain of that compartment ([@B31]; see also [@B3]). The importance of these findings cannot be overstated: this represented the first *molecular* distinction between membrane-bound compartments within the endocytic pathway and provided a framework for all future molecular analyses of receptor endocytosis and recycling or degradation. Indeed, Zerial and colleagues showed that, like Sec4, Rab5 played a key role in membrane traffic, and its function is rate limiting for endosome fusion and endocytosis ([@B11]). He and his colleagues eventually reconstituted the entire process of early endosome fusion using exclusively Rab5-binding proteins, SNARE (soluble *N*-ethylmaleimide--sensitive factor attachment protein receptor) proteins and their priming factors, liposomes, and a factor (Yip3/PRA1) to deliver prenyl Rab5 onto the liposomes (see later discussion; [@B19]).

THE Rab GTPase CYCLE AND MEMBRANE DELIVERY
==========================================

Yoshimi Takai was studying the biochemistry of a small GTPase, smg p25, which was later identified as Rab3A. He discovered a rat brain cytosol protein that inhibited the ability of smg p35/Rab3A to release GDP, the rate-limiting step in the GTPase cycle ([@B24]). He named this protein GDP-dissociation inhibitor (GDI) and showed that it could extract Rab3A from membranes in vitro but only in the presence of GDP and not GTP ([@B2]). We now know that there are two GDIs in humans and one in yeast; these proteins have the capacity to bind to all Rab GTPases, with strong preference for their GDP-bound states. At steady state, Rabs distribute themselves about half on membranes and half in cytosol (although this varies considerably between Rab proteins); all cytosolic Rabs exist in complex with GDI. The crystal structure of yeast GDI bound to Ypt1 confirmed that GDI binds to the so-called Rab "switch" regions that report on the status of the bound nucleotide; the so-called C-terminal hypervariable domain of Rab proteins is draped along the surface, and the prenyl groups bind tightly at the bottom of GDI ([@B21]). Thus GDP-bearing Rabs can be removed from membranes by cytosolic GDI proteins.

My lab was the first to report that GDI binds Rab9 GTPase with ∼20 nM affinity ([@B28]); Goody and coworkers confirmed this tight interaction for other Rab proteins ([@B36]). With this in mind, we and Zerial studied the delivery of Rab proteins onto membranes and showed that purified complexes of Rab proteins bound to GDI contain all of the information needed for accurate membrane delivery ([@B30]; [@B34]). Of importance, Rabs were delivered onto membranes in their GDP-bound forms and converted into their GTP-bound forms after a lag of ∼5 min in vitro ([@B30]; [@B34]). Because this delivery required protease-sensitive components on the surface of membranes, we postulated that it was catalyzed by a so-called GDI-displacement factor (GDF) that dissociates Rab--GDI complexes. We went on to show that a protein called Yip3/PRA1 can dissociate endosomal Rabs and deliver them to membranes ([@B29]); the Zerial lab\'s complete reconstitution of Rab5-mediated endosome fusion using purified components absolutely requires the presence of Yip3/PRA1 in membranes to accomplish Rab5 membrane association, despite the presence of a Rab5 GEF, Rabex 5, in their reactions ([@B19]).

Could a GEF be sufficient for localization? Itzen, Goody, and coworkers found a *Legionella* protein, DrrA, that can relocalize Rab1 from the early secretory pathway to the inner surface of the plasma membrane ([@B26]). DrrA is a Rab1 GEF that binds Rab1 extremely tightly and was shown to thus bypass any need for a distinct GDF activity. No endogenous Rab GEFs bind their Rab substrates as tightly as DrrA, and thus GDFs may still facilitate some Rab delivery events. Several labs artificially localized GEFs to unusual membranes such as mitochondria and succeeded in moving Rabs to those locations ([@B39]; [@B4]; [@B5]). The most important conclusion from such experiments is that GDI is promiscuous in delivering Rabs to membranes; GDI is also likely to be able to correct mistakes it might make in delivery of Rabs to membranes where the cognate GEF is not present and the Rab is, with GDP bound. Most characterized Rab GEFs are not membrane anchored; they are cytosolic proteins that can associate with other Rab effectors to activate locally specific Rab proteins. Thus one needs Rab domains to maintain Rab domains, and, in cells, Rabs usually show precise localizations ([@B37]).

These data suggest that Rab proteins are delivered to membranes by GDI and, in some cases, might use the help of GDF factors. Subsequent GEF action is also clearly important to enable Rabs to be stabilized at the site of their activation by loss of susceptibility to GDI extraction, together with active stabilization by subsequent, GTP-dependent effector binding. Several studies showed that effector binding stabilizes Rabs on membrane surfaces ([@B1]).

Rab CASCADES: ESTABLISHING THE POLARITY OF SECRETORY AND ENDOCYTIC PATHWAYS
===========================================================================

The role of Rab proteins is to recruit effectors such as motor proteins and tethering factors to facilitate downstream membrane traffic events. If you imagine that membrane flow should go from point A to point B in a pathway, you need a mechanism to template RabB after RabA on different membrane compartments. Zerial was the first to discover that effector proteins can simultaneously bind two adjacently acting Rab GTPases, thereby linking their respective localizations and functions ([@B44]; [@B38]). This discovery strongly suggested that Rab effectors organize transitions along the endocytic pathway. Nature has taken this concept one step further, using an incredibly elegant system by which RabA actually recruits to membrane surfaces the GEF that will activate the next acting Rab in the pathway ([Figure 1A](#F1){ref-type="fig"}). Thus, in yeast, Ypt31 binds the Sec 2 GEF for the subsequent-acting Sec4 Rab protein. Active Rabs are then stabilized on membranes by binding to their cognate effector proteins. In this manner, a membrane patch containing one Rab will template the establishment of a nearby domain containing the next Rab. Even better is the fact that the subsequent acting RabB also recruits a GAP for RabA to clear the membrane domain of the prior acting Rab ([Figure 1B](#F1){ref-type="fig"}). Because Rab GTPases each have distinct GEFs and GAPs, evolution has created a system by which the selectivity of each of these proteins coordinates to template an entire membrane-trafficking pathway. Although several labs were obtaining clues to the existence of such interactions, it was Peter Novick who discovered these cascades and revealed their existence in living yeast cells ([@B20]; [@B22]; see also, for example, [@B41]; [@B42]; [@B45]; [@B43]). This represented a spectacular discovery because it provided the first molecular clues about how cells create and maintain polarized secretory and endocytic pathways.

![Rab cascade model for the establishment and maintenance of the polarity of the secretory and endocytic pathways. (A) In the first scenario, a Rab GEF specific for Rab A generates active Rab A. That Rab recruits a second GEF, which activates Rab B. Similarly, Rab B recruits a GEF to activate Rab C. In this model, a membrane could have Rabs A--C intermingled or at least on a single compartment. (B) Here GAP proteins are included to remove a previous-acting Rab from a specific membrane domain. The presence of the GAP will sharpen the boundaries between individual Rab domains. Data of [@B22] support the model in B. Reprinted from [@B17].](712fig1){#F1}

SURPRISES AND UNSOLVED MYSTERIES
================================

A Special Topics Subgroup at the 2016 American Society for Cell Biology meeting discussed a number of surprises that await further analysis. We still do not know the localizations or roles of many human Rab proteins, nor do we know all of their cognate GEF or GAP identities or partner effector proteins. Rabs need to be studied in their correct tissue or cell type and at endogenous expression levels. This represents many proteins yet to be discovered because a given Rab may have ∼30 specific effector proteins ([@B9]). Effector interactions can be weak and missed by affinity chromatography. In addition, GEFs and GAPs can be more promiscuous in vitro than in vivo, and so great care must be taken in all of these analyses.

Are cascades the answer? We need to connect all of the Rab GEFs and GAPs to determine the order of membrane-trafficking events, and we need to test the consequences of altering cascade specificity to verify the predictions of this satisfying model in the broadest physiological sense. Finally, we need to reconstitute a Rab cascade de novo to fully understand how cells establish and maintain secretory and endocytic pathways.

Recently Rab proteins have been shown to be the main phosphorylation substrates for the LRRK2 kinase that is implicated in Parkinson\'s disease ([@B32]). What is the physiological consequence of phosphorylation, and how is this modification normally regulated? Transforming growth factor-β--activated kinase 1 (TAK1) also phosphorylates GDP-bearing Rab1 and blocks GDI interaction but not GEF interaction ([@B13]). This presumably stabilizes active Rab1 on membranes in a totally unanticipated manner that activates membrane trafficking. Pathogens modify Rabs in many unexpected ways, including by AMPylation and phosphocholination ([@B15]; [@B14]). Do these posttranslational modifications also occur in uninfected cells, and how (and why) are these events regulated? Finally, Rab GTPases also interact with other small GTPases via shared effector proteins, and their joint coordination is only beginning to be explored. Rab GTPases remain central regulators of membrane-trafficking pathways in healthy cells and disease. Their continued study promises to offer many more important surprises for those who study them.
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GAP

:   GTPase-activating protein

GDF

:   GDI displacement factor

GDI

:   GDP-dissociation inhibitor

GEF

:   guanine nucleotide exchange factor

Rab

:   Ras-like protein from rat brain.
